Potentiation of the leishmanicidal activity of nelfinavir in combination with miltefosine or amphotericin B

Visceral leishmaniasis (VL) is the most severe form of disease caused by the protozoan parasites belonging to the genus Leishmania [1]. Endemic in 62 countries, the World Health Organization estimates there to be about 500,000 new cases of VL every year, and that it annually causes some 70,000 deaths [1,2]. The vast majority of cases occur in the Indian subcontinent, East Africa, the regions bordering the Mediterranean, and northeastern Brazil, with Leishmania donovani and Leishmania infantum the main causal agents [2].
Source: International Journal of Antimicrobial Agents - Category: Drugs & Pharmacology Authors: Tags: Short Communication Source Type: research